DAEWON PHARMACEUTICAL CO.,LTD Logo

DAEWON PHARMACEUTICAL CO.,LTD

003220 | KO

Overview

Corporate Details

ISIN(s):
KR7003220001
LEI:
Country:
South Korea
Address:
서울특별시 성동구 천호대로 386 대원제약, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

No description available.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Regulatory Filings
[기재정정]투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 신청)
Korean 24.0 KB
2025-09-09 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 19.3 KB
2025-09-09 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의발행결과(자율공시)
Korean 6.0 KB
2025-09-02 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 34.4 KB
2025-09-02 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 31.4 KB
2025-08-29 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 16.5 KB
2025-08-25 00:00
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Korean 13.7 KB
2025-08-19 00:00
Share Issue/Capital Change
[기재정정]감자결정(종속회사의주요경영사항)
Korean 20.0 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 2.7 MB
2025-08-12 00:00
Share Issue/Capital Change
감자결정(종속회사의주요경영사항)
Korean 16.1 KB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 946.4 KB
2025-05-30 00:00
Regulatory Filings
투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 신청)
Korean 10.9 KB
2025-05-23 00:00
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Korean 13.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.3 MB
2025-04-30 00:00
Regulatory Filings
투자판단관련주요경영사항 (DW4421 제3상 임상시험계획 승인신청(미란성))
Korean 8.4 KB

Automate Your Workflow. Get a real-time feed of all DAEWON PHARMACEUTICAL CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAEWON PHARMACEUTICAL CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAEWON PHARMACEUTICAL CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
MAIA Biotechnology, Inc. Logo
Developing telomere-targeting immuno-oncology therapies for difficult-to-treat cancers.
United States of America
MAIA
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE

Talk to a Data Expert

Have a question? We'll get back to you promptly.